Senores Pharmaceuticals Limited has submitted the Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2025. This submission is in compliance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

The report, dated January 07, 2026, was duly signed and issued by Mr. Tapan Shah, Company Secretary in Practice. The announcement was made on January 12, 2026, and submitted to both BSE Limited and the National Stock Exchange of India Limited.

The report details the company's capital structure, including its equity shares position with NSDL and CDSL, physical holdings, and any pending demat status. It also confirms that the company's register of members has been updated. No material differences were noted in the share capital reconciliation for the quarter.

Separately, the announcement mentions that Senores Pharmaceuticals Limited has entered into a Share Purchase Agreement (SPA) for the acquisition of 100% share capital of Aponar Pharma Private Limited in two tranches. Upon completion, Aponar Pharma Private Limited will become a wholly-owned subsidiary of Senores Pharmaceuticals Limited.